P. van Heerde

4.4k citations

62 papers · 3.2k indexed · h-index 31

Impact in

Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment
Oncology top 2%
- Viral-associated cancers and disorders

Papers in

Pathology and Forensic Medicine 42
- Lymphoma Diagnosis and Treatment 40
Microbiology 1

Co-authors: R. Somers Erik Teske Flora E. van Leeuwen Willem J. Klokman Anton Hagenbeek Peter F. Moore Gerard R. Rutteman J. M. V. Burgers
Journals: Cancer (5 papers)Histopathology (5 papers)Blood (4 papers)Journal of Clinical Oncology (3 papers)Gut (2 papers)
Partner nations: Netherlands United States Denmark

In The Last Decade

P. van Heerde

62 papers receiving 3.1k citations

Peers

Countries citing papers authored by P. van Heerde

Since Specialization

Citations

This map shows the geographic impact of P. van Heerde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. van Heerde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. van Heerde more than expected).

Fields of papers citing papers by P. van Heerde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. van Heerde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. van Heerde. The network helps show where P. van Heerde may publish in the future.

Co-authors

The 25 scholars most cited alongside P. van Heerde, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with P. van Heerde Line = papers co-authored together P. van Heerde links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Long-Term Risk of Second Malignancy in Survivors of Hodgkin’s Disease Treated During Adolescence or Young Adulthood Journal of Clinical Oncology ·Flora E. van Leeuwen, Willem J. Klokman, Mars B. vanʼt Veer, Anton Hagenbeek, Augustinus D. G. Krol, Ursula A. O. Vetter, Michael Schaapveld, P. van Heerde, J. M. V. Burgers, R. Somers, Berthe M.P. Aleman	2000	302
2	Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: A review American Journal of Hematology ·Rafaël Fonseca, Mitsunori Yamakawa, Shôji Nakamura, P. van Heerde, Markku Miettinen, Tony W.H. Shek, O. Myhre Jensen, Marie‐Christine Rousselet, Ayalew Tefferi	1998	151
3	Diagnostic value and reproducibility of fine‐needle aspiration cytology in canine malignant lymphoma Veterinary Quarterly ·Erik Teske, P. van Heerde	1996	34
4	Actinomycosis, a sheep in wolves' clothes Lung Cancer ·Heri Wahyudi, P. van Heerde, Yvie Morley, Paul Baas	1996	3
5	Prognostic factors for treatment of malignant lymphoma in dogs Journal of the American Veterinary Medical Association ·Erik Teske, P. van Heerde, Gerard R. Rutteman, Ilene D. Kurzman, Peter F. Moore, E. Gregory MacEwen	1994	142
6	Presence of Epstein-Barr virus in extranodal T-cell lymphomas: differences in relation to site Blood ·J. Marcos A. Merinero, Mehdi Jiwa, Joan Klam, P. van der Valk, P. van Heerde, Henrique de Andrade Cenachi, 芳憲富塚, Philippe Gaulard, Carlos Rafael Arocha Rodríguez, Ankita Saikia	1994	2
7	Second cancer risk following Hodgkin's disease: a 20-year follow-up study. Journal of Clinical Oncology ·Flora E. van Leeuwen, Willem J. Klokman, Anton Hagenbeek, 杨丽洋, Alexandra W. van den Belt‐Dusebout, W. Berg, P. van Heerde, R. Somers	1994	345
8	The clinical spectrum and treatment of primary non-Hodgkin's lymphoma of the stomach Annals of Oncology ·Babs G. Taal, J. M. V. Burgers, P. van Heerde, A. A. M. Hart, R. Somers	1993	74
9	Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T‐cell or null cell phenotype Histopathology ·Peter C. de Bruin, Rob C. Beljaards, P. van Heerde, Paul van der Valk, L. Arnold Noorduyn, J. Han van Krieken, Maria Podgurskaya, Rein Willemze, Chris J.L.M. Meijer	1993	123
10	Detection of Epstein–Barr virus nucleic acid sequences and protein in nodal T‐cell lymphomas: relation between latent membrane protein‐1 positivity and clinical course Histopathology ·Peter C. de Bruin, Natasha Jiwa, Paul van der Valk, P. van Heerde, 徴収関係判例研究グループ, G. J. Ossenkoppele, J. M. M. Walboomers, C J Meijer	1993	39
11	Isolated primary oesophageal involvement by lymphoma: a rare cause of dysphagia: two case histories and a review of other published data. Gut ·Babs G. Taal, P. van Heerde, R. Somers	1993	31
12	Noncutaneous T-cell lymphomas recognition of a lymphoma type (large cell anaplastic) with a relatively favorable prognosis Cancer ·Ege Husemoglu, Vahid Naseri, Paul van der Valk, P. van Heerde, Paul J. van Diest, Miekel M. van de Sandt, Gert J. Ossenkoppele, Chris J.L.M. Meijer	1993	16
13	Differential expression of the HECA‐452 antigen (cutaneous lymphocyte associated antigen, CLA) in cutaneous and non‐cutaneous T‐cell lymphomas Histopathology ·L. Arnold Noorduyn, Rob C. Beljaards, Steven T. Pals, P. van Heerde, T Radaszkiewicz, Rein Willemze, C. J. L. M. Meijer	1992	33
14	High incidence of EBV genome in CD30‐positive non‐Hodgkin's lymphomas The Journal of Pathology ·Panagiotis Kanavaros, Natasha Jiwa, Peter C. de Bruin, Paul van der Valk, L. Arnold Noorduyn, P. van Heerde, 徴収関係判例研究グループ, A Horstman, 韩仲兵, Rein Willemze, J. M. M. Walboomers, Chris J.L.M. Meijer	1992	38
15	The Cytology of Langerhans Cell Histiocytosis (Histiocytosis X) Cytopathology ·P. van Heerde, R. Maarten Egeler	1991	32
16	Results of radiotherapy in patients with stage I orbital non-Hodgkin's lymphoma Radiotherapy and Oncology ·J.G.J. Letschert, Dionisio González, J. Oskam, Leo Koornneef, J.D.P. van Dijk, Richard Moorehouse, José Brás, P. van Heerde, Harry Bartelink	1991	74
17	Polyethylene glycol-L-asparaginase versus native L-asparaginase in canine non-Hodgkin's lymphoma European Journal of Cancer and Clinical Oncology ·Erik Teske, Gerard R. Rutteman, P. van Heerde, W. Misdorp	1990	42
18	Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease. Journal of Clinical Oncology ·Flora E. van Leeuwen, R. Somers, B.G. Taal, P. van Heerde, B. Coster, Yu-Xiu LIU, S. Horiuchi, Ailsa Hart	1989	118
19	Primary non-Hodgkin's lymphoma of the stomach: Changing aspects and therapeutic choices European Journal of Cancer and Clinical Oncology ·B.G. Taal, F.C.A. den Hartog Jager, J. M. V. Burgers, P. van Heerde, T. L. Tio	1989	40
20	Treatment results of primary stage I and II non-Hodgkin's lymphoma of the stomach Radiotherapy and Oncology ·J. M. V. Burgers, Babs G. Taal, P. van Heerde, R. Somers, F.C.A. den Hartog Jager, A. A. M. Hart	1988	62

About P. van Heerde

P. van Heerde is a scholar working on Pathology and Forensic Medicine, Microbiology, Dermatology, Oncology and Genetics, having authored 62 papers that have together received 3.2k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (40 papers), Viral-associated cancers and disorders (18 papers), Cutaneous lymphoproliferative disorders research (8 papers), Chronic Lymphocytic Leukemia Research (7 papers), Veterinary Oncology Research (6 papers), Vascular Tumors and Angiosarcomas (5 papers), T-cell and Retrovirus Studies (5 papers) and Histiocytic Disorders and Treatments (5 papers). The work is most often cited by research in Pathology and Forensic Medicine (1.9k citations), Oncology (1.2k citations), Dermatology (346 citations), Small Animals (277 citations) and Genetics (392 citations). P. van Heerde has collaborated with scholars based in Netherlands, United States and Denmark. Frequent co-authors include R. Somers, Erik Teske, Flora E. van Leeuwen, Willem J. Klokman, Anton Hagenbeek, Peter F. Moore, Gerard R. Rutteman, J. M. V. Burgers, Babs G. Taal and E. Gregory MacEwen. Their work appears in journals such as Cancer, Histopathology, Blood, Journal of Clinical Oncology and Gut.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact